SecBot SecBot
8-K ·Filed Apr 24, 2026

QTTB

Q32 Bio Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001193125-26-177178
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

Monitor for actual sales activity under this ATM program, as continuous equity issuance could pressure the stock price, especially given the company's $95M market cap. The lack of disclosed use of proceeds increases uncertainty around capital efficiency.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.47
T+0 close · Apr 24, 2026 · via day close
Latest settled
+175.69%
T+60 · $15.08
Vs SPY
+170.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $5.47entry
  2. T+1 · 7mo ago +4.57%α +5.06% · $5.72
  3. T+5 · 7mo ago −7.86%α −8.26% · $5.04
  4. T+20 · 6mo ago +29.62%α +24.66% · $7.09
  5. T+60 · 4mo ago +175.69%α +170.91% · $15.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Q32 Bio Inc. has filed an additional prospectus supplement to raise up to $75 million through its at-the-market (ATM) offering program with Cantor Fitzgerald, following the full utilization of a prior $14.2 million ATM offering. This new shelf capacity provides continued access to equity funding for the clinical-stage biotech.

Key Facts

  • Q32 Bio has fully drawn down a prior $14.2 million ATM offering with Cantor Fitzgerald
  • Filed a new prospectus supplement to offer up to $75 million in common stock via the same ATM program
  • The offering is under a shelf registration (Form S-3) declared effective April 21, 2025
  • No specific use of proceeds or pricing details disclosed in this filing

Financial Impact

$75 million in potential equity dilution

dilutioncashequity

Risk Factors

  • Significant shareholder dilution from potential $75M in new share issuance
  • Downward pressure on stock price due to overhang from ATM program
  • Lack of transparency on use of proceeds raises capital allocation concerns

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-177178
Document: d31430dex51.htm0001193125-26-177178
Document: 0001193125-26-177178-index-headers.html0001193125-26-177178
Document: 0001193125-26-177178-index.html0001193125-26-177178
Document: 0001193125-26-177178.txt0001193125-26-177178

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026